February 25, 2020 / 6:27 AM / a month ago

BRIEF-Halozyme Says FDA Accepted BLA For Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Enhanze® Technology

Feb 25 (Reuters) - Halozyme Therapeutics Inc:

* HALOZYME ANNOUNCES FDA HAS ACCEPTED BIOLOGICS LICENSE APPLICATION FOR FIXED-DOSE SUBCUTANEOUS COMBINATION OF PERJETA® AND HERCEPTIN® USING ENHANZE® TECHNOLOGY

* U.S. FOOD DRUG AND ADMINISTRATION EXPECTED TO DECIDE ON APPROVAL BY OCTOBER 18, 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below